Zhejiang University: Multiple Myeloma trials

The registry lists 11 Multiple Myeloma studies with Zhejiang University as lead sponsor. 6 are open to participants now and 0 have results posted.

Early Phase 1 7Phase 1 3Phase 2 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT06644118Phase 1
• A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaNot yet recruitingNCT04670055Early Phase 1
• CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic DiseasesRecruitingNCT04662294Early Phase 1
• APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple MyelomaRecruitingNCT04657861Early Phase 1
• CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesRecruitingNCT04603872Early Phase 1
• A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells TherapyNot yet recruitingNCT04541368Early Phase 1
• AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple MyelomaStatus unknownNCT05740891Phase 1
• A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple MyelomaStatus unknownNCT05712083Phase 2
• A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaStatus unknownNCT05430945Early Phase 1
• A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple MyelomaStatus unknownNCT05325801Phase 1
• A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple MyelomaActive, not recruitingNCT05016778Early Phase 1